Document is current

Article History

Received: 16 April 2025

Accepted: 8 September 2025

First Online: 29 October 2025

Declarations

:

: The ZENYATTA, ZARNIE, and COVASTIL trials were conducted in conformance with the International Council for Harmonisation E6 guideline for Good Clinical Practice, the principles of the Declaration of Helsinki, or the laws/regulations of the country where the research occurred, whichever provided better protection to the individual, and the trials complied with requirements of the International Council for Harmonisation E2A guideline. Ethics Committees for each site approved the protocols in each study. The COPD-ST2OP trial was performed in accordance with the principles of the Declaration of Helsinki and ethics approval given by East Midlands – Leicester South Research Ethics Committee. In all trials, patients (or their legally authorized representatives) provided written, informed consent.

: Not applicable.

: SGK has received funding from Genentech Inc., Syneos, and Teva. MM was recently a speaker and/or advisor for and/or had received research funding from Alexion, Allakos, Almirall, Alvotech, Amgen, Aquestive Therapeutics, Arcensus, argenX, AstraZeneca, Astria Therapeutics, BioCryst Pharmaceuticals, Blueprint Medicines, Celldex Therapeutics, Celltrion, Clinuvel, Cogent Biosciences, CSL Behring, Escient Pharmaceuticals, Evommune, Excellergy Therapeutics, Genentech, Inc., GSK, Incyte, Jasper Therapeutics, KalVista Pharmaceuticals, Kashiv Biosciences, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Pharvaris, Resonance Medicine, Sanofi/Regeneron, Santa Ana Bio, Septerna, Servier, Takeda, Teva, Third Harmonic Bio, ValenzaBio, Vitalli Bio, Yuhan Corporation, and Zura Bio. MW has no competing interests to declare. GA and WT are employees of F. Hoffmann-La Roche, Ltd. AD, AF, and XY are employees of Genentech, Inc. DM is an employee of Genentech, Inc. and a shareholder of F. Hoffmann-La Roche, Ltd./Genentech, Inc. CEB has received grants and consultancy fees from 4D Pharma, Areteia, AstraZeneca, Chiesi, F. Hoffmann-La Roche, Ltd., Genentech, Inc., GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals, and Sanofi paid to his institution.